HRP20130972T1 - Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti - Google Patents

Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti Download PDF

Info

Publication number
HRP20130972T1
HRP20130972T1 HRP20130972AT HRP20130972T HRP20130972T1 HR P20130972 T1 HRP20130972 T1 HR P20130972T1 HR P20130972A T HRP20130972A T HR P20130972AT HR P20130972 T HRP20130972 T HR P20130972T HR P20130972 T1 HRP20130972 T1 HR P20130972T1
Authority
HR
Croatia
Prior art keywords
spiro
heptane
dicarboxamide
ethenylene
methyl
Prior art date
Application number
HRP20130972AT
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of HRP20130972T1 publication Critical patent/HRP20130972T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/61—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (15)

1. Spoj, naznačen time, da ima formulu (I) [image] gdje W predstavlja -CH2CH2- ili -CH=CH-; Y predstavlja vezu ili (C1-C4)alkandiil-skupinu i R1 predstavlja sljedeće: • aril-skupinu ili heteroaril-skupinu, koje skupine su neovisno nesupstituirane, mono-, di- ili tri-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-C4)alkil, (C1-C4)alkoksi, (C1-C2)alkilkarbonil, (C1-C2)fluoroalkil, (C1-C2)fluoroalkoksi, nitro, cijano i fenil, gdje je fenil nesupstituiran ili mono-supstituiran s halogenom; ili • benzo[d][1,3]dioksolil; ili • ariloksi; ili • cikloheksil-skupinu ili cikloheksenil-skupinu, koje skupine su neovisno nesupstituirane ili mono-supstituirane s (C1-C4)alkilom; ili • (C1-C2)alkil-karbonil; ili • (C1-C4)alkoksi-karbonil; ili Y predstavlja zajedno s R1 (C4-C6)alkil-skupinu ili amino-(C4-C6)alkil-skupinu; Z predstavlja -C(O)NR3-* ili -CH2NR4C(O)-*, gdje zvjezdice označavaju vezu koja je spojena na R2; R2predstavlja sljedeće: • (C3-C6)cikloalkil koji je nesupstituiran ili mono-supstituiran sa sljedećima: hidroksi, hidroksi-metil, R5R6N-CH2-, heterociklil-metil ili -CONH2; ili • (C1-C6)alkil koji je nesupstituiran ili mono-supstituiran sa sljedećima: fluor, trifluorometil, (C1-C4)alkiltio, (C1-C4)alkoksi-karbonil, hidroksi, cijano, -NR5R6, -COOH, -C(O)NR7R8 ili opcijski mono-supstituiran (C1-C4)alkoksi, gdje je supstituent odabran od hidroksi i heterociklila; ili • (C1-C6)alkil koji je mono-supstituiran ◊ s (C3-C6)cikloalkilom koji je nesupstituiran ili mono-supstituiran s -NR5R6 ili hidroksi; ◊ s heterociklilom koji je nesupstituiran ili mono-supstituiran na atomu dušika sa sljedećima: (C1-C4)alkil, (C1-C2)alkil-karbonil ili tert-butoksikarbonil, i/ili mono- ili di-supstituiran na jednom ili dva atoma ugljika sa supstituentima neovisno odabranima od sljedećih: halogen, (C1-C4)alkil i (C1-C2)alkoksi-(C1-C2)alkil; ili ◊ s aril-skupinom ili heteroaril-skupinom, koje skupine su neovisno nesupstituirane, mono-, di- ili tri-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-C4)alkil, -CH2NHR9, -SO2NH2 i fenil; ili • (C3-C5)fluoroalkil koji je mono-supstituiran s heterociklilom koji je nesupstituiran ili mono- ili di-supstituiran na jednom ili dva atoma ugljika sa supstituentima neovisno odabranima od halogena i (C1-C4)alkila; ili • heterociklil koji je nesupstituiran ili mono-supstituiran na atomu dušika s (C1-C6)alkilom, benzilom ili tert-butoksikarbonilom ili mono-supstituiran na atomu ugljika s pirolidin-1-il-metilom; ili • aril-skupinu ili heteroaril-skupinu, koje skupine su neovisno nesupstituirane, mono-, di- ili tri-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-C4)alkil i fenil; ili • skupinu odabranu od sljedećih: 1-karbamoil-2-fenil-etil, 1-metoksimetil-2-feniletil, 2-morfolino-2-fenil-etil, 2-fenil-vinil, 2,2-dikloro-1-metil-ciklopropil; R3predstavlja vodik, (C1-C3)alkil ili 2-metoksi-etil; ili R2 i R3zajedno s dušikom koji ih nosi, tvore prsten od 5 do 7 člana, a taj prsten je supstituiran s amino-(C1-C4)alkilom; R4predstavlja vodik ili metil; R5predstavlja vodik, (C1-C3)alkil ili tert-butoksikarbonil; R6predstavlja vodik ili (C1-C3)alkil; R7 i R8predstavljaju međusobno neovisno vodik ili metil; ili R7 i R8zajedno s dušikom koji ih nosi, tvore pirolidin-prsten ili piperidin-prsten; i R9predstavlja vodik ili tert-butoksikarbonil; ili sol takvoga spoja.
2. Spoj formule (I) prema zahtjevu 1, naznačen time, da W predstavlja -CH2CH2- ili -CH=CH-; Y predstavlja vezu; R1predstavlja aril-skupinu ili heteroaril-skupinu, koje skupine su neovisno nesupstituirane, mono-, di- ili tri-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-C4)alkil, (C1-C4)alkoksi, (C1-C2)alkilkarbonil i (C1-C2)fluoroalkil; Z predstavlja -C(O)NR3-*, gdje zvjezdica predstavlja vezu koja je spojena na R2; R2predstavlja sljedeće: • (C3-C6)cikloalkil koji je nesupstituiran ili mono-supstituiran s hidroksi ili pirolidin-1-il-metilom; ili • (C1-C6)alkil koji je nesupstituiran ili mono-supstituiran sa sljedećima: fluor, trifluorometil, (C1-C4)alkiltio, hidroksi, cijano, -NR5R6, -C(O)NH2 ili opcijski mono-supstituiran (C1-C4)alkoksi, gdje je supstituent odabran od hidroksi i heterociklila; ili • (C1-C5)alkil koji je mono-supstituiran ◊ s heterociklilom koji je nesupstituiran ili mono-supstituiran na atomu dušika s metilom ili etilom, ili je mono- ili di-supstituiran na jednom ili dva atoma ugljika sa supstituentima neovisno odabranima od fluora, metila i metoksi-metila; ili ◊ s aril-skupinom ili heteroaril-skupinom, koje skupine su neovisno nesupstituirane, mono- ili di-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine (C1-C4)alkil i -CH2NH2; ili • (C3-C5)fluoroalkil koji je mono-supstituiran s heterociklilom; ili • heterociklil koji je nesupstituiran ili mono-supstituiran na atomu ugljika s pirolidin-1-il-metilom; R3predstavlja vodik, (C1-C3)alkil ili 2-metoksi-etil; R5predstavlja vodik, (C1-C3)alkil ili tert-butoksikarbonil; i R6predstavlja vodik ili (C1-C3)alkil; ili sol takvoga spoja.
3. Spoj formule (I) prema bilo kojem zahtjevu 1 ili 2, naznačen time, da Y predstavlja vezu, ili sol takvoga spoja.
4. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 3, naznačen time, da R1 predstavlja aril-skupinu ili heteroaril-skupinu, koje skupine su neovisno nesupstituirane ili mono-supstituirane, gdje su supstituenti odabrani iz skupine koju čine halogen, (C1-C4)alkil, (C1-C4)alkoksi, (C1-C2)alkil-karbonil i (C1-C2)fluoroalkil; ili sol takvoga spoja.
5. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 4, naznačen time, da Z predstavlja -C(O)NR3-*, gdje zvjezdica označava vezu koja je spojena na R2; ili sol takvoga spoja.
6. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 5, naznačen time, da R2 predstavlja (C3-C6)cikloalkil koji je nesupstituiran ili mono-supstituiran s hidroksi ili pirolidin-1-il-metilom; ili (C1-C6)alkil koji je nesupstituiran ili mono-supstituiran sa sljedećima: fluor, trifluorometil, (C1-C4)alkiltio, hidroksi, cijano, -NR5R6, -C(O)NH2 , ili je opcijski mono-supstituiran (C1-C4)alkoksi, gdje je supstituent odabran od hidroksi i heterociklila; ili (C1-C5)alkil koji je mono-supstituiran s heterociklilom koji je nesupstituiran ili mono-supstituiran na atomu dušika s metilom ili etilom, ili je mono- ili di-supstituiran na jednom ili dva atoma ugljika sa supstituentima neovisno odabranima od fluora, metila i metoksi-metila; ili (C1-C5)alkil koji je mono-supstituiran s aril-skupinom ili heteroaril-skupinom, koje skupine su neovisno nesupstituirane, mono- ili di-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine (C1-C4)alkil i -CH2NH2; ili (C3-C5)fluoroalkil koji je mono-supstituiran s heterociklilom; ili heterociklil koji je nesupstituiran ili mono-supstituiran na atomu ugljika s pirolidin-1-il-metilom; ili sol takvoga spoja.
7. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 5, naznačen time, da R2 predstavlja (C1-C6)alkil koji je nesupstituiran ili mono-supstituiran sa sljedećima: fluor, trifluorometil, (C1-C4)alkiltio, hidroksi, cijano, -NR5R6, -C(O)NR7R8ili je opcijski mono-supstituiran (C1-C4)alkoksi, gdje je supstituent odabran od hidroksi i heterociklila; ili sol takvoga spoja.
8. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 5, naznačen time, da R2 predstavlja (C1-C5)alkil koji je mono-supstituiran s heterociklilom koji je nesupstituiran ili mono-supstituiran na atomu dušika s metilom ili etilom, ili je mono- ili di-supstituiran na jednom ili dva atoma ugljika sa supstituentima neovisno odabranima od fluora, metila i metoksi-metila; ili sol takvoga spoja.
9. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 5, naznačen time, da R2 predstavlja (C1-C4)alkil koji je mono-supstituiran s aril-skupinom ili heteroaril-skupinom, koje skupine su neovisno nesupstituirane, mono- ili di-supstituirane, gdje su supstituenti neovisno odabrani iz skupine koju čine (C1-C4)alkil i -CH2NH2; ili sol takvoga spoja.
10. Spoj formule (I) prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: (5R*)-N5-(4-bromofenil)-(6R*)-N6-(5-amino-pentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-izobutil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(4-amino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(2-N,N-dimetil-amino-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-((3-aminometil-fenil)-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(4-piperidinil-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)N6-(pirolidin-3-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2,2-dimetil-3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)N5-(4-bromofenil)-(6R*)-N6-(4-(N,N-dietil-aminobutil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(3-hidroksi-propil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(2-karbamoil-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-pirolidin-3-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(ciklopentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-etoksi-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-pirolidinil-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2,2,2-trifluoro-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-fluoro-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(N-metil-amino)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-tetrahidrofuranil-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R)-N6-(4-hidroksi-cikloheksil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-etilsulfanil-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(5-(N,N-dietil-amino)-pent-2-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4] heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(piperidin-3-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-tert-butoksikarbonil-amino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(1-hidroksi-prop-2-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-imidazolidin-2-on-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-pirolidin-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(2-metoksi-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(1H-benzoimidazol-2-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(1-metil-pirolidin-2-il)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)N5-(4-bromofenil)-(6R*)-N6-(2-hidroksi-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6,N6-bis-(2-metoksi-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(cijano-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-1H-pirazol-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(4-aminometil-fenil)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-etil-N6-(2-dietilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-1H-imidazol-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-([1,4]-dioksan-2-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(4-hidroksi-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(4-metil-piperazin-1-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-amino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-metil-N6-(2-dimetilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N6-(4-bromofenil)-(6R*)-N6-(4-tert-butoksikarbonil-amino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(metil-tert-butoksikarbonil-amino)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-pirolidin-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-1H-[1,2,4]-triazol-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(furan-3-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(5-dimetil-amino-pentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-dimetil-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-metoksi-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(1-etil-pirolidin-2-il)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-1H-[1,2,4]-triazol-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-piperidin-3-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(N-tert-butoksikarbonil-amino)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-metil-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(2S)-1-hidroksi-4-metil-pent-2-il]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(metoksi-karbonil)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(4-aminosulfonil-fenil)-etil)-(4S,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(1-etil-5-metil-1H-pirazol-3-il)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6,N6-bis-(2-metoksi-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(4,5-dimetil-1H-imidazol-2-il)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(1S)-1-karbamoil-etil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-dietil-amino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)N5-(4-bromofenil)-(6R*)-N6-(pentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)N5-(4-bromofenil)-(6R*)-N6-(5-tert-butoksikarbonil-amino-pentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-(3-metil-butil)-piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-piridin-2-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2,2-dimetil-3-N-tert-butoksikarbonil-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(1-fenil-1H-pirazol-5-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(ciklopropil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(heksil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(1-etil-3-metil-1H-pirazol-5-il)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-fenil-2-morfolino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-dietil-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N6-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-pirolidin-2-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-morfolino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-karbamoil-cikloheksil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(1-piperidin-1-il-propan-1-on-2-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-benzil-piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-metil-N6-heksil-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3,3-dimetil-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-metil-piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-morfolino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(5-metil-1H-pirazol-4-il)propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-tert-butoksikarbonil-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-{[(3-N-tert-butoksikarbonil-aminometil)-fenil]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-propil-N6-(ciklopropilmetil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-piperidin-4-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(cikloheksil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(1S)-1-karbamoil-2-fenil-etil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4] heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(2S)-3,3-dimetil-1-(metilamino)-1-oksobutan-2-il]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(4-N-tert-butoksikarbonil-aminometil-fenil)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(N-tert-butoksikarbonil-azetidin-3-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(N-tert-butoksikarbonil-piperidin-3-il)-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(1S)-2-metoksi-1-benzil-etil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(5-metil-3-fenil-izoksazol-4-il)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-karbamoil-etil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-metoksi-propil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(tetrahidrofuran-2-il-metil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-[(2-imidazolidin-2-on-1-il)-etil]-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(ciklopropil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-hidroksi-propil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(1H-imidazol-1-il)-propil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(5-(dimetil-amino)-pentil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-pirolidin-1-il-propil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-(4-metil-piperazin-1-il)-propil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-(4,5-dimetil-1H-imidazol-2-il)-etil)-(4S*,7R*)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-bromopiridin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-metoksifenil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-kloro-piridin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-piridin-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-metil-piridin-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-pentil-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(4-metil-fenil)-metil]-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metoksikarbonil-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(cikloheksil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-metil-cikloheks-1-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-okso-heksil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-nitro-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-kloro-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-cijano-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(furan-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(1-(4-bromofenil)-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-trifluorometoksifenil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-fenoksi-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-metil-butil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-butil-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-metil-furan-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metil-benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-fenil-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-okso-pentil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(1H-imidazol-1-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-pirimidin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-bromofenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-tert-butil-izoksazol-3-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-metil-benzo[d]izotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(1H-indol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(6-fluoro-benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-etil-butil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metil-benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(benzo[2,1,3]oksadiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-tert-butil-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-fenil-[1,2,4]tiadiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(6-kloro-benzotiazol-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-(2-metil-1H-indol-1-il)-propil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(1-metil-1H-benzoimidazol-2-il)-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(1H-indol-1-il)-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(2-metoksi-fenil)-etil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4] heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-(3,5-dimetil-pirazol-1-il)-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(5-fenil-izoksazol-4-karbonil)-amino]-metil}-(4S*,7R*]-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(4-(2-okso-pirolidin-1-il)-butirilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(2-(2-kloro-fenil)-acetilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-metoksi-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-(N,N-dimetil-aminokarbonil)-propionil-amino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(2,2-dikloro-1-metil-ciklopropilkarbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(4-metoksikarbonil-butanoil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-(pentanoilamino-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(2-(2,5-dimetil-tiazo)-4-il)-acetilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil-(6R*)-6-{[(1-fenil-1H-pirazol-5-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(3-aminokarbonil-propionil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(4-metil-piridin-3-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(izobutirilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(N-etil-piperidin-4-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-piridin-3-il-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[N-(3-metoksi-propionil)-N-metil-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(2-kloro-3-fluoro-fenil-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(4-pirolidin-1-il-butanoilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(1,5-dimetil-1H-pirazol-3-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(ciklopentil-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(2-(2-metil-tiazol-4-il)-acetilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(2-(N,N-dimetil-amino)-acetilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[N-(2-(2-kloro-fenil)-acetil)-N-metil-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[N-(1,5-dimetil-1H-pirazol-3-karbonil)-N-metil-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(2-ciklopropil-acetilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-(1-metil-1H-benzoimidazol-2-il-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-1H-indol-3-il-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(butanoilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-(4-fluoro-fenil)-propionilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-[(3-fenil-akriloilamino)-metil]-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-bromo-fenil)-(6R*)-6-{[(5-kloro-1,3-dimetil-1H-pirazol-4-karbonil)-amino]-metil}-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5-karboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-fenil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-metil-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-Aaetil-tiofen-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-acetil-furan-2-il-metil)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-acetil-furan-2-il-metil)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-trifluorometil-fenil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-acetil-oksazol-5-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(4,5-dimetil-1H-imidazol-2-il)-etil)-(6R*)-N6-(4-bromofenil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-jodofenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-(izo-butil)-izoksazol-3-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-bromo-tiofen-4-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4.7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; i (5R*)-N5-(2-fluoro-4-bromofenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4.7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; ili sol takvoga spoja.
11. Spoj formule (I) prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-dimetilamino-3-oksopropil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(4-amino-4-oksobutil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-pirolidino-3-oksopropil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(2-amino-2-oksoetil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(4-etil-piperazin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-piperidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(azetidin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-morfolino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(4-metil-1,4-diazepan-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(4-metil-piperazin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-pirolidino-4-oksobutil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(2-(2-(pirolidin-1-il)-etoksi)-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-((3R,6S)-6-(pirolidin-1-ilmetil)-tetrahidro-2H-piran-3-il)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(4-acetil-piperazin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(cis-4-(pirolidin-1-il-metil)-cikloheksil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-((3R)-fluoropirolidino)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-((3S)-fluoropirolidino)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(5-pirolidino-pentil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(trans-4-(pirolidin-1-il-metil)-cikloheksil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil)-(6R*)-N6-(3-metilamino-3-oksopropil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-acetil-tiazol-5-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,6-difluoro-4-metoksi-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,3-difluoro-4-metoksi-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-fluoro-4-metoksi-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3,5-difluoro-4-metoksi-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-kloro-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-fluoro-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-trifluorometoksi-fenil-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-izopropoksi-fenil-metil(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromo-tiazol-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-acetil-oksazol-4-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromo-fenil-metil)-(6R*)-N6-(3-pirolidin-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(3-pirolidin-1-il-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-fenil-metil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromo-pirid-5-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-oksazol-2-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(izobutil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(izobutil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromo-fenil-metil)-(6R*)-N6-(izobutil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-(1H benzoimidazol-2-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(3-(1H-benzoimidazol-2-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromo-fenil-metil)-(6R*)-N6-(3-(1H-benzoimidazol-2-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metoksi-pirid-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-bromo-pirazin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-trifluorometil-piridin-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metil-piridin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(benzo[d]oksazol-6-il)-(6R*)-N6-(4-pirolidin-1-il)-butil)-(4S*,7R*)-[4.7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-metil-izoksazol-3-il-metil)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-metil-tiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-trifluorometil-1,3,4-tiadiazol-2-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromo-piridin-5-il)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(2-fluoro-etil)-(4S*,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-((2-imidazolidin-2-on)-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-amino-3-oksopropil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(4-dietilamino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(3-etoksi-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-pirolidino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromotiazol-2-il)-(6R*)-N6-(3-(4-metilpiperazin-1-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(2-dimetilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-dimetilamino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-(4-metilpiperazin-1-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-((2-imidazolidin-2-on)-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromotiazol-2-il)-(6R*)-N6-(4-dietilamino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(2-fluoroetil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(4-dietilamino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(3-(4-metilpiperazin-1-il)-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(2-dimetilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-((2-imidazolidin-2-on)-1-il-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromotiazol-2-il)-(6R*)-N6-(2-metoksi-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromotiazol-2-il)-(6R*)-N6-(3-dimetilamino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromopirid-5-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromopirid-5-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromopirid-2-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-kloropirid-5-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromotiazol-5-il-metil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-metoksifenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-metoksifenil)-(6R)-N6-(3-hidroksil-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3-fluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-kloro-piridin-5-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-metoksifenil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil-metil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-metoksifenil)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-piridin-2-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-metilfenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3-klorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-kloro-piridin-5-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il-metil)-(6R*)-N6-(piperidin4-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(2-metilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(5-amino-pentil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(4-(aminometil)fenil-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-bromo-tiazol-2-il)-(6R*)-N6-(2,2-dimetil-3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(2-metilamino-etil)-(4S*,7R*)-[4.7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(piperidin-4-il)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(3-(aminometil)-fenil-metil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(4-(aminometil)-fenil-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(2,2-dimetil-3-amino-propil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-bromofenil-metil)-(6R*)-N6-(piperidin-4-il-metil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromo-tiazol-5-il-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-metil-piridin-2-il)-(6R)-N6-(3-amino-3-oksopropil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,5-difluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,6-difluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,3-difluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,6-difluorofenil-metil)-(6R)-N6-(4-pirolidin-1-il-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(5-amino-pentil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(4-amino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3-fluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(5-amino-pentil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(piperidin-4-il)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(piperidin-4-il-metil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6,N6-(3-(aminometil)-pentan-1,5-diil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2-fluorofenil-metil)-(6R)-N6-(5-amino-pentil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,3-difluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3,5-difluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-2,5-difluorofenil-metil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(piperidin-4-il)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(izobutil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(4-tert-butoksikarbonil-amino-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(5-tert-butoksikarbonil-amino-pentil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(5-amino-pentil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(4-amino-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6,N6-(3-(aminometil)-pentan-1,5-diil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromo-tiazol-2-il)-(6R)-N6-(piperidin-4-il-metil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromo-3-fluoro-piridin-5-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-aminobutil)-(6R*)-N6-(4-bromofenil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(5-aminopentil)-(6R*)-N6-(4-bromofenil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(cikloheksen-1-il)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-tert-butil-cikloheksil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(piridin-2-il)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetil-tiazol-2-il)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-trifluorometil-tiazol-2-il)-(6R*)-N6-(4-pirolidino-butil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,4,6-trifluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,4-dimetilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(2-acetil-tiazol-4-il)metil]-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-kloro-2-fluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-metil-oksazol-2-il)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(5-acetil-tiazol-2-il)metil]-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-acetilfenil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-bromo-4-fluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-bromo-4-fluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,3,5-trifluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(4-metil-1,2,5-oksadiazol-3-il)metil]-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-fluoro-3-trifluorometilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3,5-dimetilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-acetilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-difluorometoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(2-metoksipiridin-4-il)-metil]-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-fluoro-5-trifluorometilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-acetilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-kloro-5-trifluorometilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-fluoro-5-trifluorometilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-fluoro-3-trifluorometilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(2,6-dikloropiridin-4-il)-metil]-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,5-dimetilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4,5-dimetil-tiazol-2-il)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-metoksi-5-metilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-kloro-3,6-difluorofenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-izopropoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-kloro-6-fluoro-3-metilfenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3-kloro-4-metoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(3,4-dimetoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2,4-dimetoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(3,4-dimetoksifenil)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(4-metoksifenil)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(4-bromofenil)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(3,4-dimetilfenil)etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(4-metilfenil)etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(4-fluorofenil)etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(benzo[d][1,3]dioksol-5-il)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(3-bromo-4-metoksifenil)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(2-(2,4-dimetilfenil)-etil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-(4-etoksifenil-metil)-(6R*)-N6-(4-pirolidino-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(4-klorofenil)-etil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(4-klorofenil)-etil)-(6R)-N6-(2-dimetilamino-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(4-klorofenil)etil)-(6R)-N6-(2-(piridin-2-il)etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(4-klorofenil)-etil)-(6R)-N6-(2-(4-aminosulfonil-fenil)-etil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(2,4-diklorofenil)-etil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-(4-klorofenil)-etil)-(6R)-N6-(N-izopentil-piperidin-4-il)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3,5-difluorofenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-tiazol-2-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromo-3-trifluorometilfenil)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R*)-N5-[(4-acetil-tiazol-2-il)metil]-(6R*)-N6-(2-metilamino-etil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(2,5-dimetilpirolidin-1-il)-butil)-(4S,7R)-4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(pirolidin-1-il)-pentil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(3-fluoro-4-(pirolidin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(2-(metoksimetil)pirolidin-1-il)-butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(4-(3,3-difluoropirolidin-1-il)butil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(2-bromo-3-fluoro-piridin-5-il)-(6R)-N6-(4-pirolidino-butil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(2-hidroksietil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(3-hidroksipropil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(4-hidroksibutil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(2-metil)-3-hidroksiprop-2-il)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(2-(2-hidroksietoksi)-etil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(4-hidroksi-cikloheksil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-[(1-hidroksi-cikloheksil)metil]-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(trans-4-(hidroksimetil)-cikloheksil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(cis-4-(hidroksimetil)-cikloheksil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(pirolidin-3-il)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(2-(N-metilamino)-etil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(3-(N-metilamino)-propil)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(piperidin-3-il)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-[(pirolidin-2-il)-metil]-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-[(piperidin-2-il)-metil]-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-[(piperidin-3-il)-metil]-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(5-bromotiazol-2-il)-(6R)-N6-(azetidin-3-il)-(4S,7R)-[4,7-etilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(cis-4-(aminometil)-cikloheksil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; (5R)-N5-(4-bromofenil)-(6R)-N6-(trans-4-(aminometil)-cikloheksil)-(4S,7R)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; i (5R*)-N5-(2-trifluorometil-piridin-5-il)-(6R*)-N6-(4-pirolidin-1-il-butil)-(4S*,7R*)-[4,7-etenilen-spiro[2.4]heptan]-5,6-dikarboksamid; ili sol takvoga spoja.
12. Spoj formule (I) prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava kao lijek.
13. Farmaceutski sastav, naznačen time, da kao glavni sastavni dio sadrži spoj formule (I) prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol te najmanje jedno terapeutski inertno pomoćno sredstvo.
14. Uporaba spoja formule (I) prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za prevenciju ili liječenje bolesti odabrane od sljedećih: upalne bolesti, opstrukcijske bolesti dišnih putova, alergijska stanja, infekcije posredovane HIV-retrovirusom, kardiovaskularni poremećaji, neurološka zapaljenja, neurološki poremećaji, bolovi, prionske bolesti i amiloidne bolesti; te je za modulaciju imunoloških reakcija.
15. Spoj formule (I) prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju bolesti odabrane od sljedećih: upalne bolesti, opstrukcijske bolesti dišnih putova, alergijska stanja, infekcije posredovane HIV-retrovirusom, kardiovaskularni poremećaji, neurološka zapaljenja, neurološki poremećaji, bolovi, prionske bolesti i amiloidne bolesti; te je za modulaciju imunoloških reakcija.
HRP20130972AT 2009-05-18 2013-10-14 Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti HRP20130972T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009052056 2009-05-18
PCT/IB2010/052170 WO2010134014A1 (en) 2009-05-18 2010-05-17 Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists

Publications (1)

Publication Number Publication Date
HRP20130972T1 true HRP20130972T1 (hr) 2013-11-22

Family

ID=42334028

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130972AT HRP20130972T1 (hr) 2009-05-18 2013-10-14 Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti

Country Status (25)

Country Link
US (1) US8563714B2 (hr)
EP (1) EP2432760B1 (hr)
JP (1) JP5510945B2 (hr)
KR (1) KR101724765B1 (hr)
CN (1) CN102414168B (hr)
AR (1) AR078508A1 (hr)
AU (1) AU2010250789B2 (hr)
BR (1) BRPI1013083A2 (hr)
CA (1) CA2760885C (hr)
CY (1) CY1114500T1 (hr)
DK (1) DK2432760T3 (hr)
ES (1) ES2431298T3 (hr)
HK (1) HK1167133A1 (hr)
HR (1) HRP20130972T1 (hr)
IL (1) IL216386A0 (hr)
MA (1) MA33365B1 (hr)
MX (1) MX2011012264A (hr)
NZ (1) NZ597122A (hr)
PL (1) PL2432760T3 (hr)
PT (1) PT2432760E (hr)
RU (1) RU2540274C2 (hr)
SG (1) SG176137A1 (hr)
SI (1) SI2432760T1 (hr)
TW (1) TWI490190B (hr)
WO (1) WO2010134014A1 (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
CA2706839C (en) 2007-12-18 2015-10-20 Actelion Pharmaceuticals Ltd Aminotriazole derivatives as alx agonists
RU2544862C2 (ru) 2009-06-09 2015-03-20 Актелион Фармасьютиклз Лтд Фторированные аминотриазольные производные
WO2010143158A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
EP2585054A1 (en) * 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
EP2640699B1 (en) * 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
JP5923108B2 (ja) 2010-12-07 2016-05-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのヒドロキシル化アミノトリアゾール誘導体
AU2011340146B2 (en) 2010-12-07 2016-05-19 Idorsia Pharmaceuticals Ltd Oxazolyl-methylether derivatives as ALX receptor agonists
CA2841095A1 (en) * 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
US8440684B2 (en) * 2011-07-11 2013-05-14 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8729096B2 (en) 2012-02-16 2014-05-20 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators
JP6101788B2 (ja) * 2012-05-16 2017-03-22 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ＡＬＸ受容体アゴニストとしての１−（ｐ−トリル）シクロプロピル置換架橋スピロ［２．４］ヘプタン誘導体
MA37618B1 (fr) * 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
AR096686A1 (es) * 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
CA2917811C (en) * 2013-07-16 2021-08-31 Allergan, Inc. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
RU2016105310A (ru) * 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CN105705484B (zh) * 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
JP6251084B2 (ja) * 2014-03-07 2017-12-20 住友ゴム工業株式会社 タイヤ形成用の剛性中子
TWI662039B (zh) 2014-05-13 2019-06-11 瑞士商諾華公司 用於誘發軟骨生成之化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708765A4 (en) 1993-07-16 1996-06-26 Merck & Co Inc PIPERAZINYLCAMPHER DERIVATIVES SUBSTITUTED AS OXYTOCIN ANTAGONISTS
AU2003214249A1 (en) 2002-04-03 2003-10-13 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
WO2005047899A2 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CA2810292C (en) 2004-05-14 2015-09-29 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
CA2706839C (en) 2007-12-18 2015-10-20 Actelion Pharmaceuticals Ltd Aminotriazole derivatives as alx agonists
RU2544862C2 (ru) 2009-06-09 2015-03-20 Актелион Фармасьютиклз Лтд Фторированные аминотриазольные производные
WO2010143158A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
EP2585054A1 (en) * 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity

Also Published As

Publication number Publication date
JP5510945B2 (ja) 2014-06-04
MA33365B1 (fr) 2012-06-01
US8563714B2 (en) 2013-10-22
PL2432760T3 (pl) 2013-12-31
CA2760885A1 (en) 2010-11-25
DK2432760T3 (da) 2013-09-08
KR20120041695A (ko) 2012-05-02
SG176137A1 (en) 2011-12-29
RU2540274C2 (ru) 2015-02-10
RU2011151277A (ru) 2013-06-27
ES2431298T3 (es) 2013-11-25
NZ597122A (en) 2013-06-28
BRPI1013083A2 (pt) 2016-04-05
AU2010250789B2 (en) 2015-05-14
EP2432760A1 (en) 2012-03-28
TWI490190B (zh) 2015-07-01
WO2010134014A1 (en) 2010-11-25
AU2010250789A1 (en) 2012-01-19
AR078508A1 (es) 2011-11-16
CN102414168B (zh) 2014-05-21
CN102414168A (zh) 2012-04-11
JP2012527445A (ja) 2012-11-08
EP2432760B1 (en) 2013-07-17
IL216386A0 (en) 2012-01-31
KR101724765B1 (ko) 2017-04-07
SI2432760T1 (sl) 2013-10-30
US20120115841A1 (en) 2012-05-10
PT2432760E (pt) 2013-10-21
CA2760885C (en) 2017-03-28
CY1114500T1 (el) 2016-10-05
TW201100080A (en) 2011-01-01
MX2011012264A (es) 2011-12-12
HK1167133A1 (en) 2012-11-23

Similar Documents

Publication Publication Date Title
HRP20130972T1 (hr) Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti
DE60219698T2 (de) Glukokinase beeinflussende Verbindungen
AU766193B2 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
SK4752001A3 (en) 2-aminothiazole derivatives, process for their preparation, and their use as antitumor agents
SK287373B6 (sk) Použitie arylmetylkarbonylaminotiazolových derivátov na výrobu liečiva na liečenie bunkových proliferačných chorôb
WO2006011631A2 (en) Thiazole derivatives having vap-1 inhibitory activity
MX2013001363A (es) N- ((6-amino-piridin-3-il)-metil) -heteroaril-carboxamidas como inhibidoras de calicreina de plasma.
JP2014532640A5 (hr)
JP2013507449A5 (hr)
EP2451794A2 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
EP1718624A1 (en) Benzamide derivatives and their use as glucokinase activating agents
IL272845B2 (en) Compounds and preparations for inhibiting IRE1
EP2164494A1 (en) Methods of treatment
JP2009533315A (ja) 抗菌剤
MXPA06009511A (en) Benzamide derivatives and their use as glucokinae activating agents
MXPA06009510A (en) Compounds